Laleh Amiri-Kordestani, MD, and Eric Winer, MD, will moderate a Tuesday afternoon special session on new drug approvals, featuring insights from oncology experts at the U.S. Food and Drug Administration.

Mirat Shah, MD, will serve as one of the moderators for a Tuesday afternoon session that will reinforce the need for dosage and regimen optimization in breast cancer drug development and clinical trial design.

Christine Desmedt, PhD, will moderate a Tuesday afternoon session looking at technological advances that have driven important discoveries in the field of the tumor immune microenvironment.

Adrian Lee, PhD, will moderate a Tuesday afternoon session on evolving technologies and applications for liquid biopsy.